Close Menu

NEW YORK — The US Food and Drug Administration last week granted separate Emergency Use Authorizations (EUAs) for PCR-based SARS-CoV-2 tests developed by Biocollections Worldwide and Gnomegen.

Biocollections' SARS-CoV-2 assay is an RT-PCR test designed to detect the nucleocapsid (N) gene of the virus in upper respiratory specimens, such as nasal swabs and oropharyngeal swabs, and bronchoalveolar lavage. It runs on Abbott's automated m2000 system and may only be performed at the Miami, Florida-based company's CLIA laboratory.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.